Back to journals
Academic JournalOpen Access

Frontiers in Pharmacology

47 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 47 psychedelic papers Blossom tracks from Frontiers in Pharmacology line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Frontiers in Pharmacology carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

13papers published in 2018

+225% vs 2017

19 published by 2018

Browse papers→

Don't read as the journal's total output: only the 47 of 47 tracked psychedelic papers from Frontiers in Pharmacology with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Frontiers in Pharmacology publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Addiction & Substance Use
17
Depressive Disorders
15
Anxiety Disorders
10
Interpersonal Functioning & Social Connectedness
8
Neuroimaging & Brain Measures
7
Medicinal Chemistry & Drug Development
7
Personality & Trait Factors
6
Set & Setting
6
Other
32

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Frontiers in Pharmacology cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Psilocybin
13
Ayahuasca
13
DMT
7
LSD
7
Ibogaine
5
MDMA
3
Mescaline
3
5-MeO-DMT
2
Other
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Frontiers in Pharmacology has 47 tracked papers indexed in Blossom (2016–2026) from 282 authors, most often covering Psilocybin, Ayahuasca and DMT, across Substance Use Disorders (SUD), Depressive Disorders and Healthy Volunteers.

Published Papers

Open Accessindividual

Clinical improvement following an integrative iboga microdosing protocol in post-concussive and hypoxic brain injury syndromes: a case series

This case series (n=3) describes three people with persistent symptoms after traumatic brain injury or hypoxic brain injury who took a 6-week iboga microdosing protocol alongside psychotherapy and supportive care. All three reported marked improvement, and two said their symptoms had fully resolved at long-term follow-up, but the authors do not claim the treatment caused these changes.

Published
Journal
Frontiers in Pharmacology
Authors
Tabaac, B. J., Carhart-Harris, R. L., Yung, T.
Open Accessmeta

Effects of hallucinogenic drugs on the human heart

This review summarises evidence that classic hallucinogens (bufotenin, psilocin/psilocybin, LSD, ergotamine/ergometrine, DMT and 5‑MeO‑DMT) act via cardiac 5‑HT receptors to produce positive inotropic and chronotropic effects in humans, increasing contractile force and heart rate and potentially provoking arrhythmias. It highlights these cardiovascular actions as an under‑appreciated risk of hallucinogen use.

Published
Journal
Frontiers in Pharmacology
Authors
Neumann, J., Dhein, S., Kirchhefer, U., Hofmann, B., Gergs, U.
Open Accessindividual

Overcoming the clinical challenges of traditional ayahuasca: a first-in-human trial exploring novel routes of administration of N,N-Dimethyltryptamine and harmine

This open-label within-subject study (n=10) compared the oral administration of a capsule (containing DMT and harmine) with combined intranasal administration of an oromucosal harmine tablet and an intranasal DMT spray at two doses. The research aimed to improve the pharmacokinetics and tolerability profiles of ayahuasca-analogue formulations. Results indicate that the combined buccal/intranasal administration substantially attenuated common side effects and yielded significantly improved pharmacokinetic profiles. This suggests it may be an innovative approach for the safe and patient-oriented administration of DMT/harmine for treating affective disorders.

Published
Journal
Frontiers in Pharmacology
Authors
Dornbierer, D. A., Marten, L., Mueller, J., Mueller, M. J., Aicher, H. D., Boxler, M. I., Kometer, M., Kosanic, D., von Rotz, R., Puchkov, M., Kraemer, T., Landolt, H-P., Seifritz, E., Scheidegger, M.
Open Accessindividual

Pharmacological effects of methylone and MDMA in humans

In a randomised, double‑blind, placebo‑controlled crossover trial in 17 experienced psychostimulant users, a single oral dose of methylone (200 mg) produced sympathomimetic effects and stimulant/entactogenic subjective effects similar to MDMA (100 mg) but with a faster onset and shorter duration. These results indicate methylone’s acute pharmacological profile and abuse potential in humans are comparable to those of MDMA.

Published
Journal
Frontiers in Pharmacology
Authors
Poyatos, L., Pérez-Mañá, C., Hladun, O., Núñez-Montero, M., De La Rosa, G., Martín, S., Barriocanal, A. M., Carabias, L., Kelmendi, B., Taoussi, O., Busardò, F. P., Fonseca, F., Torrens, M., Pichini, S., Farré, M., Papaseit, E., Lutfy, K., Baumann, M. H.
Open Accessindividual

Psilocybin sex-dependently reduces alcohol consumption in C57BL/6J mice

This mice study found that psilocybin reduced alcohol consumption for three days, but this effect was only present in male mice.

Published
Journal
Frontiers in Pharmacology
Authors
Alper, K., Cange, J., Sah, R., Schreiber-Gregory, D., Sershen, H., Vinod, K. Y.
Open Accessindividual

Changes in mental health, wellbeing and personality following ayahuasca consumption: Results of a naturalistic longitudinal study

In a naturalistic longitudinal study of 53 ayahuasca‑naïve attendees, a single facilitated ceremony produced broad 1‑month improvements in depression, anxiety, stress, substance use, personality traits, relationships and spirituality. Baseline characteristics—particularly high negative emotionality and body dissociation and low self‑efficacy—predicted greater benefit while facets of the mystical experience did not, indicating potential for personalised treatment and warranting randomised controlled trials.

Published
Journal
Frontiers in Pharmacology
Authors
Perkins, D., Pagni, B. A., Sarris, J., Barbosa, P., Chenhall, R.

Quick Facts

Papers Indexed
47
h-Index
175
Open Access
Yes
Publisher
Frontiers Media
Country
Switzerland
Website
Visit